TIGIT review highlights unresolved questions for pancreatic cancer immunotherapy

A new review in the Journal of Pancreatology examines T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) as an immune checkpoint target for cancer immunotherapy.¹

Continued interest in TIGIT biology persists after a mixed clinical development trajectory for anti-TIGIT antibodies. TIGIT is mechanistically attractive because it is expressed on several immune effector and regulatory cell populations and interacts with ligands implicated in tumor immune evasion, but the class has not yet established a broad regulatory role in solid tumors.

What did the TIGIT review address?

The review of TIGIT as a “pivotal immune checkpoint” in cancer immunotherapy examined the inhibitory receptor’s ability to limit antitumor immune activity, in part through interaction with poliovirus receptor–related ligands such as CD155 and through functional opposition to the costimulatory receptor CD226.² This biology has supported development of monoclonal antibodies intended to block TIGIT signaling, often in combination with programmed death ligand 1 (PD-L1) or programmed cell death protein 1 (PD-1) blockade.

The clearest published clinical signal for the class has come from early randomized testing in non–small cell lung cancer. In the phase 2 CITYSCAPE trial, tiragolumab plus atezolizumab improved investigator-assessed outcomes compared with placebo plus atezolizumab in PD-L1–selected metastatic non–small cell lung cancer, with no major unexpected safety pattern reported in the publication.³ However, phase 2 activity in one tumor type does not establish generalizable efficacy across gastrointestinal malignancies, including pancreatic cancer.

Why does TIGIT matter in pancreatic cancer immunotherapy?

The review’s placement in the Journal of Pancreatology suggests relevance to pancreatic cancer research, where checkpoint inhibition has had a limited role for most patients. Pancreatic ductal adenocarcinoma is typically characterized by late diagnosis, aggressive biology, and an immunosuppressive tumor microenvironment. Standard systemic treatment for metastatic disease remains based primarily on cytotoxic chemotherapy, including multiagent regimens such as Folfirinox in appropriately selected patients.⁴

This context helps explain why investigators continue to evaluate immune checkpoints beyond PD-1 and PD-L1. A TIGIT-directed strategy may be hypothesized to enhance cytotoxic T-cell and natural killer cell function or reduce regulatory T-cell–mediated suppression, but those hypotheses require tumor-specific validation. Pancreatic cancer has repeatedly shown that immune mechanisms identified in melanoma or lung cancer cannot be assumed to translate into clinically meaningful benefit.

For drug developers, the main question is whether TIGIT inhibition can identify a responsive biologic subset, rational combination partner, or timing strategy in pancreatic tumors. Potential combinations could involve PD-1/PD-L1 inhibitors, chemotherapy, radiation, stromal modulation, vaccines, or myeloid-directed approaches, but the accessible source does not report any such clinical data from the review.

What are the next steps for anti-TIGIT development?

The immediate value of the review may be in synthesizing mechanistic rationale and identifying gaps in translational research. Key unanswered questions include whether TIGIT expression, CD155 expression, CD226 status, T-cell exhaustion phenotypes, or spatial immune profiling can help select patients for TIGIT-directed therapy.

Safety is also a practical issue for combination development. Although TIGIT blockade is designed as immune modulation rather than direct cytotoxic therapy, additive immune-related adverse events remain possible when paired with PD-1 or PD-L1 inhibitors. Published early clinical data have generally supported feasibility of combination treatment in selected populations, but broader safety and efficacy depend on tumor type, disease setting, and comparator regimen.³

The accessible release does not indicate whether the Journal of Pancreatology review proposes a specific development pathway, names investigational agents, or evaluates ongoing trials. Until tumor-specific clinical data are available, TIGIT should be viewed as a biologically credible but still unproven checkpoint target in pancreatic cancer and other hard-to-treat solid tumors.

References

1. A new review in the Journal of Pancreatology explores TIGIT as a pivotal immune checkpoint for cancer immunotherapy. Published June 5, 2026. Accessed June 5, 2026. EurekAlert. https://www.eurekalert.org/news-releases/1130786
2. Johnston RJ, Comps-Agrar L, Hackney J, et al. (2014 Nov). The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. https://pubmed.ncbi.nlm.nih.gov/25465800/
3. Cho BC, Abreu DR, Hussein M, et al. (2022 Jun). Tiragolumab plus atezolizumab versus placebo plus atezolizumab as first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. https://pubmed.ncbi.nlm.nih.gov/35576957/
4. Conroy T, Desseigne F, Ychou M, et al. (2011 May 12). FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. https://www.nejm.org/doi/full/10.1056/NEJMoa1011923